The Street’s Key Stock Analysts Research Reports


Daily HeffX-LTN reviews dozens of  the Street’s Key analysts research reports to ID new trading and investing ideas for HeffX-LTN readers.

Some reports cover stocks to buy, and others cover stocks to sell or avoid.

Below is a list of stocks analysts have singled out to look at carefully Tuesday, as follows:

Fiserv Inc. (NASDAQ:FISV) was reiterated as Buy and the target price was raised to 120 at Argus.

Fulcrum Therapeutics Inc. (NASDAQ:FULC) was started with a Buy rating and assigned a 19 price objective at Merrill Lynch.

Genmab A/S (NASDAQ:GMAB) was up 0.7% at $18.94 Friday and was indicated up almost 2% more at $19.30 Monday. RBC Capital Markets started it as Outperform, Guggenheim started it as Buy and Morgan Stanley started it as Overweight.

Humana Inc. (NYSE:HUM) was raised to Overweight from Neutral and the target price was raised to 345 from 300 at Cantor Fitz.

New Relic Inc. (NYSE:NEWR) was raised to Buy from Hold with 93 target price at Argus.

News Corp. (NASDAQ:NWSA) was raised to Outperform from Neutral at Credit Suisse, noting a focus on value after earnings.

ONEOK Inc. (NYSE:OKE) was raised to Buy from Neutral and the target price was raised to 75 from 69 at UBS.

Symantec Corp. (NASDAQ:SYMC) was reiterated as Hold at Argus following its enterprise sale to Broadcom.

Uber Technologies Inc. (NYSE:UBER) was reiterated as Outperform and the target price was raised to 56.00 from 54 at JMP Securities. Uber Vs Lyft earnings and analyst scorecard was not what the post-earnings initial headlines and reactions might have indicated.

Stay tuned…

The following two tabs change content below.

Paul Ebeling

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of “The Red Roadmaster’s Technical Report” on the US Major Market Indices™, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

You must be logged in to post comments :